Epsilogen announces CTA approval for Phase Ib trial of MOv18 IgE in platinum-resistant ovarian cancer
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application for the Phase Ib trial of MOv18 IgE has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
The Phase Ib study is expected to initiate later in 2024 and will evaluate the efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer (PROC).
Dr Tim Wilson, Chief Executive Officer of Epsilogen, said: “This CTA is another significant milestone for Epsilogen and the clinical development of MOv18 IgE. We look forward to progressing MOv18 IgE into a Phase Ib efficacy study later this year as we continue to demonstrate the potential of IgE antibodies as a new, differentiated class of cancer treatments.”
About MOv18 IgE
MOv18 IgE is an immunoglobulin E (IgE) antibody targeting the folate receptor alpha (FR alpha) antigen. FR alpha is present on a variety of cancers including ovarian, endometrial, lung and triple negative breast cancer. Epsilogen has successfully completed a Phase I safety study of MOv18 IgE in PROC patients. The results of the study, published in Nature Communications, found MOv18 IgE to be safe and well tolerated, with evidence of anti-tumour activity observed. Epsilogen, alongside its partner Lonza, also announced the successful completion of large-scale Good Manufacturing Practice (GMP) manufacturing of MOv18 IgE earlier this year.
About the Phase Ib study
The Phase Ib study is designed to confirm the safety and tolerability of MOv18 IgE and demonstrate efficacy in PROC. Following the dose escalation, an expansion cohort will be recruited to make a preliminary assessment of the anti-tumour activity of MOv18 IgE at a selected dose. In addition, delay to disease progression will be assessed along with a number of translational elements to generate further understanding of MOv18 IgE in the study population.
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently successfully completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in platinum-resistant ovarian cancer patients later this year. The company is also developing a pipeline of IgE therapies in oncology as well as proprietary platforms including IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) with enhanced functionality.
Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others. Find out more at epsilogen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240707808760/en/
Contacts
Communications advisor to Epsilogen Ltd:
Simon Conway
Senior Managing Director
FTI Consulting
epsilogen@fticonsulting.com
+44 (0)20 3727 1000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Launches Ask IBKR: AI Tool Delivers Instant Portfolio Answers15.10.2025 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Ask IBKR, an AI-powered tool that delivers instant portfolio insights through natural language queries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015991473/en/ “With Ask IBKR, we’re introducing a natural language-based way for investors to interact with their portfolio data,” said Milan Galik, Chief Executive Officer at Interactive Brokers. “Instead of navigating across screens, clients can simply ask, ‘What sector am I underweight compared to the S&P 500?’ and get an instant, visualized answer.” Categories of queries include: Portfolio Metrics: Compare performance against benchmarks, identify valuation changes over time, and highlight periods of outperformance or underperformance Allocation Analysis: Analyze sector exposure, compare returns across asset classes, and assess performance by instrument type Holdings
Multiply Group Announces Plans to Acquire 2PointZero and Ghitha Holding via Share Swap15.10.2025 16:36:00 EEST | Press release
Multiply Group (ADX: MULTIPLY), the Abu Dhabi-based investment holding company that invests in and operates businesses globally, today announced that its Board has approved a proposal to acquire 2PointZero and Ghitha Holding through a share swap transaction. Under the proposed terms, Multiply Group would offer shares to acquire 2PointZero and Ghitha Holding, followed by the issuance of new shares to complete the transaction. The transaction is currently under review and remains subject to shareholder and regulatory approvals. 2PointZero is a transformational investment company with scalable assets in energy, mining, and financial services, serving as an AI enabler and energy transition accelerator driving a smarter, more sustainable future. Ghitha Holding is a leading conglomerate spanning agriculture, food production, and distribution operations that play a vital role in food security. Together, these businesses represent complementary strengths across the Energy and Consumer sectors,
Svante Hails Nobel Prize in Chemistry, Validating Metal-Organic Framework Technology is Critical for Commercial Carbon Capture15.10.2025 16:30:00 EEST | Press release
Svante, a leader in solid sorbent-based carbon capture and removal filter technology, celebrated the announcement of the 2025 Nobel Prize in Chemistry last week, which honored scientists Susumu Kitagawa, Richard Robson and Omar Yaghi for their groundbreaking work in the metal-organic framework (MOF) field. The Royal Swedish Academy of Sciences awarded the prize for the development of MOFs, citing their "enormous potential" and unique molecular architecture that creates spacious, porous materials capable of capturing and storing specific substances, including carbon dioxide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015855374/en/ Svante scientist holding a jar of metal-organic framework (MOF), a relatively new class of nanomaterials for carbon capture mentioned in the Nobel Prize for Chemistry Richard Laliberté, Svante’s COO and President of Svante OEM&D, stated, “The Nobel Committee’s recognition of the very class
New NIQ Report: Quality, Convenience, and Hygiene to Drive Growth in Home Appliances Market in 202615.10.2025 16:00:00 EEST | Press release
NielsenIQ (NYSE: NIQ) today released its Home Appliances Outlook 2026: What consumers want report, which reveals the macro forces that will shape the Home Appliances industry in 2026 and the product innovation most likely to drive growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015103990/en/ NIQ projects a 2% year-over-year sales growth between 2024 and 2025 for global Consumer Tech and Durable Goods (T&D), with household appliances playing a significant part in that growth. Global sales of T&D products overall grew 4.6% in the first half of 2025 compared with the same period in 2024, with consumers spending more per item in all sectors except Major Domestic Appliances (MDA). Consumers remain cautious in their spending but are willing to pay for appliances that offer smart convenience, multifunctionality, energy efficiency, or health and hygiene benefits. New Market Realities Reshape the Home Appliances Landscape C
Impartner Launches HyperscalerGTM, the First Unified Partner-to-Marketplace Automation15.10.2025 16:00:00 EEST | Press release
Impartner, the global leader in partner management and partner marketing automation, today announced the launch of HyperscalerGTM, a disruptive new solution that unifies the entire partner-to-cloud-marketplace journey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015648514/en/ The launch of HyperscalerGTM represents the most significant advancement in partner automation in a decade, introducing a disruptive solution that unifies the entire partner-to-cloud-marketplace journey. For the first time ever, vendors can enable partners to register deals, collaborate with hyperscaler field teams, and transact directly in cloud marketplaces all from within a single, automated workflow. The result is a faster, simpler path from partner registration to closed marketplace revenue. “HyperscalerGTM is the most significant advancement in partner automation in a decade,” said Joe Wang, CEO of Impartner. "By integrating the deal registr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom